Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas

Endocrine-Related Cancer

Volumn 15, Issue 3, 2008, Pages 693-700

  Karagiannis, Asterios ^a   Tziomalos, Konstantinos ^a,b   Kakafika, Anna I ^a   Athyros, Vasilios G ^a   Harsoulis, Faidon ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMILORIDE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANRENOATE POTASSIUM; DEOXYCORTICOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; MINERALOCORTICOID ANTAGONIST; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE;

ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE PRODUCING ADENOMA; ANTIHYPERTENSIVE ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLOOD PRESSURE REGULATION; BREAST TENDERNESS; CANCER CHEMOTHERAPY; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; GYNECOMASTIA; HORMONE ACTION; HUMAN; HYPERTENSION; HYPERVOLEMIA; INOPERABLE CANCER; LAPAROSCOPIC SURGERY; LIBIDO DISORDER; LONG TERM CARE; LOW DRUG DOSE; MENSTRUATION DISORDER; MONOTHERAPY; MUSCLE CRAMP; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRIMARY HYPERALDOSTERONISM; REVIEW; RISK ASSESSMENT; TUMOR VOLUME;

ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL ADENOMA; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; HUMANS; HYPERALDOSTERONISM; RECEPTORS, ALDOSTERONE;

EID: 53849117774     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-08-0094     Document Type: Review

References (84)

1. Abdelhamid S, Müller-Lobeck H, Pahl S, Remberger K, Bönhof JA, Walb D & Röckel A 1996 Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients. Archives of Internal Medicine 156 1190-1195.
2. Ahmad N, Romero DG, Gomez-Sanchez EP & Gomez-Sanchez CE 2004 Do human vascular endothelial cells produce a1dosterone? Endocrinology, 145 3626-3629.
3. Armanini D, Karbowiak I, Goi A, Mantero F & Funder JW 1985 In vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay. Clinical Endocrinology 23 341-347.
4. Assalia A & Gagner M 2004 Laparoscopic adrenalectomy. British Journal of Surgery 91 1259-1274.
5. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ & Wolf PA 1994 Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. Journal of the American Medical Association 271 840-844.
6. Biglieri EG & Schambelan M 1973 Management of primary aldosteronism. In Hypertension: Mechanisms and Management, pp 493-498. Eds G Onesti, KE Kim & JH Moyer. New York: Grune and Stratton.
7. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED Jr, Sos TA, Atlas SA, Müller FB, Acevedo R, Ulick S & Laragh JH 1994 Diagnosis and treatment of primary hyper-aldosteronism. Annals of Internal Medicine 121 877-885.
8. Brand E, Chatelain N, Mulatero P, Féry I, Curnow K, Jeunemaitre X, Corvol P, Pascoe L & Soubrier F 1998 Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 32 198-204.
9. Brilla CG & Weber KT 1992 Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovascular Research 26 671-677.
10. Brown MJ & Hopper RV 1999 Calcium-channel blockade can mask the diagnosis of Conn's syndrome. Postgraduate Medical Journal 75 235-236.
11. Brown JJ, Davies DL, Ferriss JB, Fraser R, Haywood E, Lever AF & Robertson JI 1972 Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. BMJ 2 729-734.
12. Brunt LM, Moley JF, Doherty GM, Lairmore TC, DeBenedetti MK & Quasebarth MA 2001 Outcomes analysis in patients undergoing laparoscopic adrenalectomy for hormonally active adrenal tumors. Surgery, 130 629-634.
13. Carpenè G, Rocco S, Opocher G & Mantero F 1989 Acute and chronic effect of nifedipine in primary aldosteronism. Clinical and Experimental Hypertension 11 1263-1272.
14. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R & Sechi LA 2008 Cardiovascular outcomes in patients with primary aldosteronism after treatment. Archives of Internal Medicine 168 80-85.
15. Celen O, O'Brien MJ, Melby JC & Beazley RM 1996 Factors influencing outcome of surgery for primary aldosteronism. Archives of Surgery 131 646-650.
16. Conn JW 1955 Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. Journal of Laboratory and Clinical Medicine 45 3-17.
17. Craft J 2004 Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure. BUMC Proceedings 17 217-220.
18. Curnow KM, Tusie-Luna MT, Pascoe L, Natarajan R, Gu JL, Nadler JL & White PC 1991 The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. Molecular Endocrinology 5 1513-1522.
19. Davis WW, Newsome HH Jr, Wright LD Jr, Hammond WG, Easton J & Bartter FC 1967 Bilateral adrenal hyperplasia as a cause of primary a1dosteronism with hypertension, hypokalemia and suppressed renin activity. American Journal of Medicine 42 642-647.
20. Dupont A 1985 Disappearance of spironolactone-induced gynaecomastia during treatment with potassium canrenoate. Lancet 2 731.
21. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G & Mulatero P 2006 Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 91 454-459.
22. Fardella CE, Mosso L, Gómez-Sánchez C, Cortés P, Soto J, Gómez L, Pinto M, Huete A, Oestreicher E, Foradori A et al. 2000 Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. Journal of Clinical Endocrinology and Metabolism 85 1863-1877.
23. Favia G, Lumachi F, Scarpa V & D'Amico DF 1992 Adrenalectomy in primary aldosteronism: a long-term follow-up study in 52 patients. World Journal of Surgery 16 680-683.
24. Ferriss JB, Beevers DG, Boddy K, Brown JJ, Davies DL, Fraser R, Kremer D, Lever AF & Robertson JI 1978 The treatment of low-renin ('primary') hyperaldosteronism. American Heart Journal 96 97-109.
25. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, Dechend R, Wellner M, Meiners S, Maser-Gluth C et al. 2005 Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 111 3087-3094.
26. Fukudome Y, Fujii K, Arima H, Ohya Y, Tsuchihashi T, Abe I & Fujishima M 2002 Discriminating factors for recurrent hypertension in patients with primary aldosteronism after adrenalectomy. Hypertension Research 25 11-18.
27. Ganguly A & Weinberger MH 1981 Triamterene-thiazide combination: alternative therapy for primary aldosteronism. Clinical Pharmacology and Therapeutics 30 246-250.
28. Garthwaite SM & McMahon EG 2004 The evolution of aldosterone antagonists. Molecular and Cellular Endocrinology 217 27-31.
29. de Gasparo M, Joss U, Ramjoué HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J, Schmidlin J et al. 1987 Three new epoxy-spironolactone derivatives: characterization in vivo and in vitro. Journal of Pharmacology and Experimental Therapeutics 240 650-656.
30. Ghose RP, Hall PM & Bravo EL 1999 Medical management of aldosterone-producing adenomas. Annals of Internal Medicine 131 105-108.
31. Giacchetti G, Roncom V, Turchi F, Agostinelli L, Mantero F, Rilli S & Boscaro M 2007 Atdosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. Journal of Hypertension 25 177-186.
32. Gockel I, Heintz A, Polta M & Junginger T 2007 Long-term results of endoscopic adrenalectomy for Conn's syndrome. American Surgeon 73 174-180.
33. Gob BK, Tan YH, Yip SK, Eng PH & Cheng CW 2004 Outcome of patients undergoing laparoscopic adrenalectomy for primary hyperaldosteronism. Journal of the Society of Laparoendoscopic Surgeons 8 320-325.
34. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M & Klemm SA 1993 Evidence that primary aldosteronism may not be uncommon: 12% incidence amona antihypertensive drug trial volunteers. Clinical and Experimental Pharmacology and Physiology 20 296-298.
35. Griffing GT & Melby JC 1985 The therapeutic effect of a new angiotensin-converting enzyme inhibitor, enalapril maleate, in idiopathic hyperaldosteronism. Journal of Clinical Hypertension 1 265-276.
36. Griffing GT, Cole AG, Aurecchia SA, Sindler BH, Komanicky P & Melby JC 1982 Amiloride in primary hyperaldosteronism. Clinical Pharmacology and Therapeutics 31 56-61.
37. Harris DA, Au-Yong I, Basnyat PS, Sadler GP & Wheeler MH 2003 Review of surgical management of aldosterone secreting tumours of the adrenal cortex. European Journal of Surgical Oncology 29 467-474.
38. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF. Corvol P & Menard J 1987 Efficacy and tolerance of spironolactone in essential hypertension. American Journal of Cardiology 60 820-825.
39. Karagiannis A, Tziomalos K, Dona K, Pyrpasopoulou A, Kartali N, Athyros V & Zamboulis C 2005 Bilateral renal artery stenosis and primary aldosteromsm in a diabetic patient. QJM 98 913-915.
40. Karagiannis A, Tziomalos K, Kakafika A, Florentin M & Athyros VG 2007 Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism. Nephrology, Dialysis, Transplantation 22 293.
41. Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika Al, Pagourelias ED, Anagnostis P, Athyros VG & Mikhailidis DP 2008 Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opinion on Pharmacotherapy 9 509-515.
42. Lim PO, Jung RT & MacDonald TM 1999 Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. British Journal of Clinical Pharmacology 48 756-760.
43. Lim PO, Young WE & MacDonald TM 2001 A review of the medical treatment of primary aldosteronism. Journal of Hypertension 19 353-361.
44. Lo CY, Tam PC, Kung AW, Lam KS & Wong J 1996 Primary aldosteronism. Results of surgical treatment. Annals of Surgery 224 125-130.
45. Lumachi F, Ermani M, Basso SM, Armanini D, Iacobone M & Favia G 2005 Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved hypertension and review of the literature. American Surgeon 71 864-869.
46. Mantero F. Fallo F, Opocher G, Armanini D, Boscaro M & Scaroni C 1981 Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism. Clinical Science 61 289s-293s.
47. Mantero F. Opocher G, Rocco S, Carpenè G & Armanini D 1995 Long-term treatment of mineralocorticoid excess syndromes. Steroids 60 81-86.
48. McMahon GT & Dluhy RG 2004 Glucocorticoid-remediable aldosteronism. Cardiology in Review 12 44-48.
49. Ménard J, Gonzalez MF, Guyene TT & Bissery A 2006 Investigation of aldosterone-synthase inhibition in rats. Journal of Hypertension 24 1147-1155.
50. Meria P, Kempf BF, Hermieu JF, Plouin PF & Duclos JM 2003 Laparoscopic management of primary hyperaldosteronism: clinical experience with 212 cases. Journal of Urology 169 32-35.
51. Meyer A. Brabant G & Behrend M 2005 Long-term follow-up after adrenalectomy for primary aldosteronism. World Journal of Surgery 29 155-159.
52. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME & Mourad JJ 2005 Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology 45 1243-1248.
53. Mulatero P, Morello F & Veglio F 2004 Genetics of primary aldosteronism. Journal of Hypertension 22 663-670.
54. Nishikawa T & Omura M 2000 Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomedicine and Pharmacotherapy 54 83s-85s.
55. Obara T, Ito Y, Okamoto T, Kanaji Y, Yamashita T, Aiba M & Fujimoto Y 1992 Risk factors associated with post-operative persistent hypertension in patients with primary aldosteronism. Surgery 112 987-993.
56. Pang TC, Bambach C, Monaghan JC, Sidhu SB, Bune A, Delbridge LW & Sywak MS 2007 Outcomes of laparoscopic adrenalectomy for hyperaldosteronism. ANZ Journal of Surgery 77 768-773.
57. Proye CA, Mulliez EA, Carnaille BM, Lecomte-Houcke M, Decoulx M, Wémeau JL, Lefebvre J, Racadot A, Ernst O, Huglo D et al. 1998 Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Surgery 124 1128-1133.
58. Raizada MK, Francis SC, Wang H, Gelband CH, Reaves PY & Katovich MJ 2000 Targeting of the renin-angiotensin system by antisense gene therapy: a possible strategy for the long-term control of hypertension. Journal of Hypertension 18 353-362.
59. Ramires FJ, Mansur A, Coelho O, Maranhão M, Gruppi CJ, Mady C & Ramires JA 2000 Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. American Journal of Cardiology 85 1207-1211.
60. Rocha R & Stier CT Jr 2001 Pathophysiological effects of aldosterone in cardiovascular tissues. Trends in Endocrinology and Metabolism 12 308-314.
61. Rossi H, Kim A & Prinz RA 2002 Primary hyperaldosteronism in the era of laparoscopic adrenalectomy. American Surgeon 68 253-256.
62. Sapienza P & Cavallaro A 1999 Persistent hypertension after removal of adrenal tumours. European Journal of Surgery 165 187-192.
63. Saruta T, Suzuki H, Takita T, Saito I, Murai M & Tazaki H 1987 Pre-operative evaluation of the prognosis of hypertension in primary aldosteronism owing to adenoma. Acta Endocrinologica 116 229-234.
64. Sawka AM, Young WF, Thompson GB, Grant CS, Farley DR, Leibson C & van Heerden JA 2001 Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Annals of Internal Medicine 135 258-261.
65. Schirpenbach C & Reincke M 2007 Primary aldosteronism: current knowledge and controversies in Conn's syndrome. Nature Clinical Practice. Endocrinology & Metabolism 3 220-227.
66. Shen WT, Lim RC, Siperstein AE, Clark OH, Schecter WP, Hunt TK, Horn JK & Duh QY 1999 Laparoscopic vs open adrenalectomy for the treatment of primary hyperaldosteronism. Archives of Surgery 134 628-631.
67. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B & Delcayre C 1998 Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. Journal of Biological Chemistry 273 4883-4891.
68. Simon D, Goretzki PE, Lollert A & Röher HD 1993 Persistent hypertension after successful adrenal operation. Surgery 114 1189-1195.
69. Sirén J, Välimäki M, Huikuri K, Sivula A, Voutilainen P & Haapiainen R 1998 Adrenalectomy for primary aldosteronism: long-term follow-up study in 29 patients. World Journal of Surgery 22 418-421.
70. So A, Duffy DL, Gordon RD, Jeske YW, Lin-Su K, New MI & Stowasser M 2005 Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. Journal of Hypertension 23 1477-1484.
71. Stimpel M, Ivens K, Wambach G & Kaufmann W 1988 Are calcium antagonists helpful in the management of primary aldosteronism? Journal of Cardiovascular Pharmacology 12 S131-S134.
72. Stokes GS, Monaghan JC, Ryan M & Woodward M 2001 Efficacy of an angiotensin II receptor antagonist in managing hyperaldosteronism. Journal of Hypertension 19 1161-1165.
73. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C & Smithers BM 2003 High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. Journal of Hypertension 21 2149-2157.
74. Sywak M & Pasieka JL 2002 Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism. British Journal of Surgery 89 1587-1593.
75. Takeda Y, Miyamori I, Inaba S, Furukawa K, Hatakeyama H, Yoneda T, Mabuchi H & Takeda R 1997 Vascular aldosterone in genetically hypertensive rats. Hypertension 29 45-48.
76. Tamura Y, Adachi J, Chiba Y, Mori S, Takeda K, Kasuya Y, Murayama T, Sawabe M, Sasano H, Araki A et al. 2008 Primary aldosteronism due to unilateral adrenal microadenoma in an elderly patient: efficacy of selective adrenal venous sampling. Internal Medicine 47 37-42.
77. Tanabe A, Naruse M, Naruse K, Hase M, Yoshimoto T, Tanaka M, Seki T, Demura R & Demura H 1997 Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertension Research 20 85-90.
78. Taymans SE, Pack S, Pak E, Torpy DJ, Zhuang Z & Stratakis CA 1998 Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. Journal of Clinical Endocrinology and Metabolism 83 1033-1036.
79. Veglio F, Pinna G, Bisbocci D, Rabbia F, Piras D & Chiandussi L 1990 Efficacy of nicardipine slow release (SR) on hypertension, potassium balance and plasma aldosterone in idiopathic aldosteronism. Journal of Human Hypertension 4 579-582.
80. Weigel RJ, Wells SA, Gunnells JC & Leight GS 1994 Surgical treatment of primary hyperaldosteronism. Annals of Surgery 219 347-352.
81. Wisgerhof M, Carpenter PC & Brown RD 1978 Increased adrenal sensitivity to angiotensin II in idiopathic hyperaldosteronism. Journal of Clinical Endocrinology and Metabolism 47 938-943.
82. Yee KM, Pringle SD & Struthers AD 2001 Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. Journal of the American College of Cardiology 37 1800-1807.
83. Young WF 2007 Primary aldosteronism: renaissance of a syndrome. Clinical Endocrinology 66 607-618.
84. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR & van Heerden JA 2004 Role for adrenal venous sampling in primary aldosteronism. Surgery 136 1227-1235.